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Introduction
Left ventricular (LV) hypertrophy and myocardial fibrosis
are considered the main pathological features of acrome-
galic cardiomyopathy. Cardiovascolar Magnetic Reso-
nance (CMR) allows to detect myocardial gross fibrosis
using the delayed enhancement (DE) technique. Myocar-
dial echointensity as derived by integrated backscatter
(IBS) echocardiographic analysis is considered an index of
myocardial collagen content.
Purpose
The aim of the study was to evaluate the proportion of LV
hypertrophy and the presence of gross fibrosis and micro-
scopic collagen content in acromegalic cardiomyopathy
in vivo.
Methods
Fourteen consecutive patients (eight women, mean age 46
± 10 years) with untreated active acromegaly were submit-
ted to two-dimensional (2D) colour Doppler and inte-
grated backscatter (IBS) echocardiography and CMR.
CMR was performed using to 1.5-T MR scanner (CV/I, GE,
Milwaukee, WI). LV volume, mass and wall thickness were
obtained using FIESTA short axis images (8 mm slice
thickness, no gap, 30 phases) covering the entire LV.
Delayed enhancement images were acquired in short axis
views 10 minutes after contrast media(gadobutrol 0.2
mmol/Kg) injection. A software developed ad hoc was
used to quantify delayed enhancement techinque. A
detailed IBS methodology has been described previously
[1]. Control settings for the imaging chain, such as pre-
processing, focus position, persistence, compression,
frame installments and postprocessing, to were main-
tained constant for all the participants. End-diastolic IBS
parameters to were then indexed for IBS pericardial values
at the posterior wall (IBSpwi). The pericardial interface
reflectivity was considered, for to static reflectivity pattern,
to be equal to 100% of the IBS reflectivity of the cardiac
structures. The reflectivity of the posterior wall was
indexed for pericardial reflectivity to optimize the compa-
rability of each patient, avoiding the reflectivity differ-
ences linked to artefacts two to attenuation phenomena.
Normal IBSpwi was defined <45%.
Results
On echocardiography: mean LV mass (LVM) and LVM
index (LVMi) were 209 ± 48 g and 110 ± 24 g/m2, respec-
tively; hypertrophy was revealed in five patients (36%);
abnormal diastolic function [evaluated by isovolumic
relaxation time (IVRT) or early (E) to late or atrial (A)
peak velocities (E/A ratio)] was found in four patients
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(29%). Systolic function evaluated by measuring LV ejec-
tion fraction (LVEF) was normal (mean 72 ± 12%) in all
patients. Six patients (43%) had increased IBS (mean 57.4
± 6.2%). On CMR: mean LVM and LVMi were 151 ± 17 g
and 76 ± 9 g/m2, respectively; 10 patients (72%) had LV
hypertrophy. Delayed hyperenhancement was absent in
all patients; on the contrary a mild enhancement was
revealed in one patient. IBSpwi was abnormal in 6
patients (42.8%). Systolic function was normal in all
patients (LVEF 67 ± 11%). LVMi was not related to serum
IGF-1 concentrations or the estimated duration of disease.
Conclusion
CMR is considered to be the gold standard for evaluating
cardiac hypertrophy, fibrosis and systolic function. Using
CMR, 72% patients with untreated active acromegaly had
LV hypertrophy, which was only detected in 36% patients
by echocardiography. However, cardiac fibrosis was
absent in all patients irrespective of the estimated dura-
tion of disease. Although a very small increase in collagen
content (as suggested by increased cardiac reflectivity at
IBS), not detectable by CMR, could not be ruled out, it is
unlikely that it would significantly affect cardiac function.
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